Abstract: The present disclosure provides a cross-linked material comprising conjugates which include two or more separate affinity ligands bound to a non-polymeric framework, wherein the molecular weight of the non-polymeric framework is less than 10,000 Da; and multivalent cross-linking agents that non-covalently bind the affinity ligands of the conjugates and thereby cross-link the conjugates to form a cross-linked material, wherein the non-covalent bonds between the multivalent cross-linking agents and the affinity ligands are competitively dissociated in the presence of excess amounts of a target molecule. The present disclosure also provides methods of making and methods of using these materials. In other aspects, the present disclosure provides exemplary conjugates including conjugates for use in glucose responsive cross-linked materials.
Type:
Grant
Filed:
January 27, 2010
Date of Patent:
January 27, 2015
Assignees:
National Institutes of Health (NIH), The United States of America Dept. of Health and Human Services (DHHS), The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR)
Abstract: Cidofovir or foscarnet based compounds having an amino acid or dipeptide esters are provided as prodrugs.
Type:
Grant
Filed:
March 16, 2009
Date of Patent:
November 22, 2011
Assignees:
TSRL, Inc., National Institute of Health (NIH), The United States of America as represented by the Department of Health and Human Services (DHHS), The United States of America as represented by the NIH Division of Extramural Inventions and Technology Resources (DEITR)
Inventors:
John Hilfinger, Charles E. McKenna, Boris A. Kashemirov, Chi Pham, Kanokkarn Saejueng, Larryn Peterson
Abstract: Peptides able to inhibit or activate the translocation or function of ?PKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for ?PKC-selective agonists and antagonists.
Type:
Grant
Filed:
May 12, 2004
Date of Patent:
June 29, 2010
Assignees:
National Institute of Health (NIH), The United States of America as represented by the Department of Health and Human Services, The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR)